Key facts
- This page summarizes Thomas M. Moriarty's Form 4 filing for CVS HEALTH Corp (CVS).
- 1 reported transaction and 6 derivative rows are listed below.
- Accepted by SEC: 04 Jan 2023, 15:16.
Thomas M. Moriarty - 31 Dec 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)
- Reporting relationship
- EVP & General Counsel
- Issuer ticker
- CVS
- Reported as of
- 31 Dec 2022
- Net transaction value
- -$27,291,251
- SEC form
- 4
- Accepted by SEC
- 04 Jan 2023, 15:16:52 UTC
- Prior SEC filing
- 16 Dec 2022
- Next SEC filing
- 12 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas M. Moriarty
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas M. Moriarty filed Form 4 for CVS HEALTH Corp (CVS) on 04 Jan 2023.
Change
- Previous filing in this sequence was filed on 16 Dec 2022.
- Current net transaction value: -$27,291,251.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CVS
transaction
Common Stock
Tax liability
- Transaction value
- $27,291,251
- Shares
- -292,856
- Change %
- -48%
- Price
- $93.19
- Shares after
- 315,273
- Date
- 31 Dec 2022
- Ownership
- Direct
- Footnotes
- F1
CVS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 159,120
- Date
- 31 Dec 2022
- Ownership
- By GRAT
CVS
holding
Stock Unit
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 47,325
- Date
- 31 Dec 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CVS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 71,696
- Date
- 31 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 71,696
- Exercise price
- $104.82
- Footnotes
- F2
CVS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 24,248
- Date
- 31 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,248
- Exercise price
- $78.05
- Footnotes
- F3
CVS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 50,502
- Date
- 31 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,502
- Exercise price
- $54.19
- Footnotes
- F4
CVS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 98,558
- Date
- 31 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 98,558
- Exercise price
- $58.34
- Footnotes
- F5, F6
CVS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 116,622
- Date
- 31 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 116,622
- Exercise price
- $74.30
- Footnotes
- F7
CVS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 46,777
- Date
- 31 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 46,777
- Exercise price
- $101.09
- Footnotes
- F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Surrender of shares in payment of withholding taxes due upon the vesting and settlement of the PSUs.
Footnote F2
Option became exercisable in four equal annual installments, commencing 4/1/2017.
Footnote F3
Option became exercisable in four equal annual installments, commencing 4/3/2018.
Footnote F4
Option became exercisable in four equal annual installments, commencing 4/1/2020.
Footnote F5
The number of shares subject to the option were calculated using a 30-day average price.
Footnote F6
Option became exercisable in four equal annual installments, commencing 4/1/2021.
Footnote F7
Option became exercisable in four equal annual installments, commencing 4/1/2022.
Footnote F8
Option becomes exercisable in four equal annual installments, commencing 4/1/2023.